Bioinformatics, RNA sequencing, and targeted bisulfite sequencing analyses identify the role of PROM2 as a diagnostic and prognostic biomarker.
Rattachement africain : pk, it, ba, sa, Égypte. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVES: Prominin 2 (PROM2) gene has been reported as a molecular biomarker of human cancers; however, its role is still controversial. This study was therefore arranged to seek the role of PROM2 in different cancers with Bioinformatics and in vitro analyses. METHODS: A combination of bioinformatics and molecular experiments. RESULTS: Through the utilization of Bioinformatics analysis, it was observed that in 19 out of the 24 human cancers studied, there was a significant increase in the expression of PROM2 compared to the respective control samples. Additionally, the overexpression of PROM2 was linked specifically to a decrease in overall survival (OS) among breast cancer (BRCA), lung adenocarcinoma (LUAD), and uterine corpus endometrial carcinoma (UCEC) patients. Furthermore, advanced molecular investigations were conducted, encompassing RNA sequencing (RNA-seq) as well as targeted bisulfite sequencing (bisulfite-seq) assessments of PROM2. These analyses were performed across an array of lung cancer cell lines (A549, ABC-1, EBC-1, and LK-2) and a normal control lung cell line (MRC-9). Results of these analysis revealed overexpression and reduced methylation of PROM2 within lung cancer cell lines, relative to the corresponding control cell line. This suggests that PROM2 assumes a substantial function in the advancement and course of BRCA, LUAD, and UCEC cancers. Subsequent pathway analysis revealed that genes enriched by PROM2 are actively engaged in four pivotal pathways. Additionally, intriguing associations were observed between PROM2 expression, tumor purity, infiltration of CD8+ T immune cells, and genetic modifications. Moreover, we also predicted a few MicroRNAs (miRNAs), transcription factors (TFs), and potential drugs that could help to understand and better manage these cancers via designing appropriate therapies targeting PROM2. CONCLUSION: Via this study, we effectively revealed PROM2 overexpression as a potential diagnostic and prognostic biomarker of survival in BRCA, LUAD, and UCEC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
Où se fait cette recherche
-
Liaquat University of Medical & Health Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Scuola Superiore Meridionale pays non établi dans la noticeUniversité ou école supérieure
-
Kidney Centre pays non établi dans la noticeÉtablissement de santé
-
Pakistan Kidney and Liver Institute and Research Center pays non établi dans la noticeÉtablissement de santé
-
Pir Mehr Ali Shah Arid Agriculture University pays non établi dans la noticeUniversité ou école supérieure
-
University of Faisalabad pays non établi dans la noticeUniversité ou école supérieure
-
University of Agriculture Faisalabad pays non établi dans la noticeUniversité ou école supérieure
-
International University of Sarajevo pays non établi dans la noticeUniversité ou école supérieure
-
King Saud University pays non établi dans la noticeUniversité ou école supérieure
-
Sinai University Égypte (code pays fourni par la source)Université ou école supérieure
-
Liaquat University of Medical and Health Sciences Jamshoro 76090 Department of Physiology pays non établi dans la noticeUniversité ou école supérieure
-
Department of Community Medicine pays non établi dans la noticeInstitution
Liaquat University of Medical & Health Sciences, Scuola Superiore Meridionale et Kidney Centre, avec 9 autres affiliations. Pays d’affiliation : Égypte.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.